Your session is about to expire
What is Kengreal
CangrelorThe Generic name of this drug
Treatment SummaryCangrelor is a medication used to prevent blood clots in people who are having a procedure to open blocked heart arteries (percutaneous coronary intervention). It works faster than other oral drugs (such as prasugrel, ticagrelor, and clopidogrel) that are used for the same purpose, and does not need to be metabolized in order to take effect. It was approved by the FDA in 2015 and is administered intravenously.
Kengrealis the brand name
Kengreal Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Kengreal
Cangrelor
2015
2
Approved as Treatment by the FDA
Cangrelor, also known as Kengreal, is approved by the FDA for 7 uses like Myocardial Infarction and Coronary Revascularization .Myocardial Infarction
Coronary Revascularization
prophylaxis of Stent thrombosis
Thrombosis
prophylaxis of repeat coronary revascularization
Myocardial Infarction
Angioplasty
Effectiveness
How Kengreal works in the bodyCangrelor is a drug that stops platelets from sticking together and forming clots. Platelets are a type of blood cell that normally stick together to form clots when there is damage to a blood vessel. Cangrelor stops this process by blocking a protein called P2Y12, which helps platelets stick together when it binds to a molecule called ADP. Cangrelor works in the same way as other drugs like clopidogrel and ticlopidine, but it acts more quickly and only lasts for a short time.
When to interrupt dosage
The measure of Kengreal is contingent upon the diagnosed condition, such as Myocardial Infarction, prophylaxis of reoccurring coronary revascularization and prophylaxis of Stent thrombosis. Dosage fluctuates according to the method of delivery, as indicated in the table below.Condition
Dosage
Administration
Myocardial Infarction
50.0 mg,
Intravenous, , Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
prophylaxis of repeat coronary revascularization
50.0 mg,
Intravenous, , Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
prophylaxis of Stent thrombosis
50.0 mg,
Intravenous, , Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Thrombosis
50.0 mg,
Intravenous, , Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Coronary Revascularization
50.0 mg,
Intravenous, , Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Angioplasty
50.0 mg,
Intravenous, , Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Myocardial Infarction
50.0 mg,
Intravenous, , Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Warnings
Kengreal ContraindicationsCondition
Risk Level
Notes
Hemorrhage
Do Not Combine
Common Kengreal Drug Interactions
Drug Name
Risk Level
Description
Abrocitinib
Major
The risk or severity of bleeding and thrombocytopenia can be increased when Cangrelor is combined with Abrocitinib.
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Cangrelor.
Andexanet alfa
Major
The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Cangrelor.
Anti-inhibitor coagulant complex
Major
The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Cangrelor.
Antihemophilic factor (recombinant), PEGylated
Major
The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Cangrelor.
Kengreal Novel Uses: Which Conditions Have a Clinical Trial Featuring Kengreal?
10 active studies are underway to assess the potential of Kengreal to prevent repeat coronary revascularization, Myocardial Infarction and Stent thrombosis prophylaxis.Condition
Clinical Trials
Trial Phases
Thrombosis
0 Actively Recruiting
Coronary Revascularization
1 Actively Recruiting
Phase 4
prophylaxis of repeat coronary revascularization
0 Actively Recruiting
Angioplasty
7 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 2, Phase 3
Myocardial Infarction
0 Actively Recruiting
Myocardial Infarction
0 Actively Recruiting
prophylaxis of Stent thrombosis
0 Actively Recruiting
Patient Q&A Section about kengreal
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Kengreal used for?
"KENGREAL is a drug that prevents blood clots from forming in the heart's blood vessels during a procedure called percutaneous coronary intervention."
Answered by AI
What type of drug is cangrelor?
"Cangrelor is a medication used during percutaneous coronary intervention to reduce the risk for complications such as myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST)."
Answered by AI
How is cangrelor given?
"Cangrelor is a medication used in conjunction with PCI, given as an IV bolus and immediately followed by an infusion for 2 hours or until the procedure is completed, whichever is longer."
Answered by AI
What is the other name for cangrelor?
"Cangrelor is a drug that prevents blood clots from forming. It is sold under the brand name Kengreal in the United States, CANREAL in India ( MSN Labs ) and Kengrexal in the European Union. It was approved by the FDA in June 2015 as an antiplatelet drug for intravenous application."
Answered by AI